IDEAYA Biosciences, Inc.

NASDAQ:IDYA

Biotechnology

Healthcare
$26.49 -1.45%

-$0.45 today

Market cap
$2.56B
Beta
-0.05
P/E (TTM)
-19.5
EPS (TTM)
-$1.58
52W Low $20.50High $39.28

Volume 1.45M

Average 1.44M

IDYA Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

IDEAYA Biosciences, Inc.NASDAQ: IDYA

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue dips below year-ago levels

Q1 FY2026 cost of revenue of $1.14M fell 98.4% year over year, behind the +232.7% change in trailing-twelve-month cost of revenue. Sequentially, it fell 98.7% from the prior quarter. Over 3 fiscal years it compounded at +29.8% a year.

Context

  • Cost of revenue amounted to 2.1% of revenue in FY2025, down 52.7 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -98.4% toward the trailing-twelve-month pace of +232.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.14M-98.7% QoQ
Last fiscal yearDec 2025
$4.59M+19.8% YoY
LTMMar 2026
$244.96M+232.7% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-98.4%——
1 year+19.8%——
3-year CAGR+29.8%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
4.59M USD
Year-over-year change
+19.8%
4-year CAGR
+27.7%

Cost of Revenue vs competitors

How IDYA compares with its peers on the latest reported figures

  • IDYA's LTM Mar 2026 cost of revenue of $244.96M is the highest of the 9 companies compared; the peer median is $5.2M.
  • Its year-over-year change of +232.7% is the highest of 5, against a peer median of +63.5%.
  • Cost of revenue amounts to 108.7% of revenue for IDYA, versus a peer median of 14.9%.
IDYA Competitors Peer median
Cost of Revenue for IDYA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$244.96M +232.7%+29.8%108.7%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$94.76M -56.9%-53.2%13.5%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$21.94M ——77.7%
RVMDRevolution Medicines, Inc.LTM Jun 2026$9.24M ———
VSTMVerastem, Inc.LTM Mar 2026$8.06M ——16.3%
COGTCogent Biosciences, Inc.LTM Jun 2026$2.33M +101.6%——
ERASErasca, Inc.LTM Sep 2026$1.47M +76.2%+5.6%—
TNGXTango Therapeutics, Inc.LTM Sep 2026$942K +50.7%——
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$391K ——2.3%
Peer median (excluding IDYA) $5.2M+63.5%-23.8%14.9%

Competitors are the stored peer set for IDYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.94M50.93M23.39M7M218.71M
Cost of Revenue1.73M2.1M4.01M3.83M4.59M
Gross Profit26.22M48.83M19.38M3.17M214.12M
Gross Margin93.8%95.9%82.9%45.2%97.9%
Research & Development58.16M89.54M129.51M294.67M314.7M
Selling, General & Admin18.33M21.8M24.3M35.47M63.32M
Operating Expenses76.48M111.33M153.81M330.14M373.43M
Depreciation & Amortization1.73M2.1M4.01M3.83M4.59M
EBITDA(48.04M)(56.55M)(108.95M)(270.64M)(109.11M)
EBITDA Margin-171.9%-111.0%-465.9%-3866.3%-49.9%
Operating Income(50.27M)(62.5M)(134.43M)(326.98M)(159.31M)
Operating Margin-179.9%-122.7%-574.9%-4671.1%-72.8%
Interest Income506K3.85M21.47M52.5M45.62M
Interest Expense00000
Other Income / Expenses506K3.85M21.47M52.5M45.62M
Income Before Tax(49.76M)(58.66M)(112.96M)(274.48M)(113.7M)
Pre-Tax Margin-178.1%-115.2%-483.0%-3921.1%-52.0%
Income Tax Expense00000
Net Income(49.76M)(58.66M)(112.96M)(274.48M)(113.7M)
Net Margin-178.1%-115.2%-483.0%-3921.1%-52.0%
EPS (Basic)(1.41)(1.42)(1.96)(3.36)(1.28)
EPS (Diluted)(1.41)(1.42)(1.96)(3.36)(1.28)
Weighted Avg Shares35.25M41.44M57.52M81.68M88.49M
Weighted Avg Shares (Diluted)35.25M41.44M57.52M81.68M88.49M

IDEAYA Biosciences, Inc.

NASDAQ:IDYA

Intrinsic Alpha fair value

Locked

Current Price

$26.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.